

## PERSONAL INFORMATION

Ulla Wändel Liminga

## WORK EXPERIENCE

January 1994–September 2007

**Non-clinical assessor**

Medical Products Agency (Sweden)

April 1996–December 1997

**Scientific administrator**

European Medicines Agency (United Kingdom)

October 2007–October 2008

**Acting Scientific Director Pharmacology/Toxicology**

Medical Products Agency (Sweden)

November 2008–Present

**Scientific Director Pharmacology/Toxicology**

Medical Products Agency (Sweden)

July 2012–June 2015

**PRAC alternate**

Medical Products Agency (Sweden)

July 2015–Present

**PRAC delegate**

Medical Products Agency (Sweden)

## EDUCATION AND TRAINING

January 1984–January 1988

**Master of Science in Pharmacy**

Uppsala University, Faculty of Pharmacy (Sweden)

January 1988–October 1993

**Doctor in Medical Sciences**

Uppsala University, Faculty of Medicine (Sweden)

## ADDITIONAL INFORMATION

**Expertise**

Non-clinical assessment

Clinical assessment, particularly safety

Biologics

Use of medicines in pregnancy

EU-procedures

**Publications**

Ceridono M, Tellner P, Bauer B, Barroso J, Alépée N, Corvi R, De Smedt A, Fellows M, Gibbs N, Heisler E, Jacobs A, Jirova D, Jones D, Kandárová H, Kasper D, Kinyamu Akunda J, Krul C, Learn D, Liebsch M, Lynch A, Muster W, Nakamura K, Nash JF, Pfannenbecker U, Phillips G, Robles C, Rogiers V, Van De Water F, Wändel Liminga U, Vohr HW, Wattlelos O, Woods J, Zuang V, Kreysa J, Wilcox P.

The 3T3 neutral red uptake phototoxicity test: Practical experience and implications for phototoxicity testing – The report of an ECVAM–EFPIA workshop August 2012

Regul Toxicol Pharmacol. 2012 Jun 9;63(3):480–488. [Epub ahead of print]

Leconte I, Bailey G, Davis-Bruno K, Hew KW, Kim J, Silva Lima B, Liminga U, Moffit J, De Schaepprijver L, Schmitt G, Tassinari M, Thompson K, Hurtt M.

Value of juvenile animal studies.

Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):292-303

Beyer BK, Chernoff N, Danielsson BR, Davis-Bruno K, Harrouk W, Hood RD, Janer G, Liminga UW, Kim JH, Rocca M, Rogers J, Scialli AR.

ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation.

Birth Defects Res B Dev Reprod Toxicol. 2011 Feb;92(1):36-51.

Dencker L, Oskarsson A, Tegnell A, Liminga UW.

[The level of mercury in Pandemrix is not associated with increased health risk]. [Article in Swedish] Läkartidningen. 2009 Dec 22;106(52):3522.

Bremer S, Balduzzi D, Cortvrint R, Daston G, Eletti B, Galli A, Huhtaniemi I, Laws S, Lazzari G, Liminga U, Smitz J, Spano M, Themmen A, Tilloy A, Waalkens-Behrends I.

The effects of chemicals on mammalian fertility. The report and recommendations of ECVAM Workshop 53—the first strategic workshop of the EU ReProTect Project.

Altern Lab Anim. 2005 Aug;33(4):391-416.

Liminga U and Lima B.

Non-clinical development of fixed combinations – A European Regulatory Perspective Int J Pharm Med 2004: 18 (3)

Liminga U.

Preclinical assessments of European Union marketing authorisation applications for immunomodulatory biopharmaceuticals.

Hum Exp Toxicol. 2000 Apr;19(4):257-60.

Liminga U, Andren PE, Öhlund LS, Gunne LM.

High frequency oral movements induced by long-term administration of amperozide but not FG5803 in rats.

Psychopharmacology (Berl). 1996 Feb;123(3):223-30.

Ellison G, Liminga U, Keys A.

Oral movement patterns induced in rats by local infusions into striatum depend upon the regimen of prior neuroleptic exposure.

Psychopharmacology (Berl). 1995 Sep;121(2):259-66.

Andrén PE, Levin ED, Liminga U, Gunne L.

Behavioural and neurochemical consequences of ibotenic acid lesion in the subthalamic nucleus of the common marmoset.

Brain Res Bull. 1995;36(3):301-7.

Johnson AE, Liminga U, Lidén A, Lindefors N, Gunne LM, Wiesel FA.

Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain.

Neuroscience. 1994 Dec;63(4):1003-20.

Liminga U, Gunne LM.

Intranigral stimulation of oral movements by [Pro9] substance P, a neurokinin-1 receptor agonist, is enhanced in chronically neuroleptic-treated rats.

Behav Brain Res. 1993 Oct 21;57(1):93-9.

Liminga U, Johnson AE, Andrén PE, Gunne LM.

Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat.

Pharmacol Biochem Behav. 1993 Oct;46(2):427-33.

Liminga U.

Selective neurokinin NK1 and NK2 receptor agonists infused in the substantia nigra of the rat increase vacuous chewing.

Eur J Pharmacol. 1993 Apr 28;235(2-3):177-81.

Mitchell IJ, Crossman AR, Liminga U, Andren P, Gunne LM.

Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey.

Mov Disord. 1992;7(1):32-7.

Liminga U, Johansson PE, Gunne L.

Intranigral tachykinin NK3 receptor agonist elicits oral movements in rats.

Pharmacol Biochem Behav. 1991 Mar;38(3):617-20.

Maggio R, Liminga U, Gale K.

Selective stimulation of kainate but not quisqualate or NMDA receptors in substantia nigra evokes limbic motor seizures.

Brain Res. 1990 Oct 1;528(2):223-30.

Liminga U, Johansson P, Nylander I, Gunne LM.

Intranigral infusion of enkephalins elicits dyskinetic biting in rats.

Psychopharmacology (Berl). 1989;99(3):299-303.

#### Projects

#### Memberships

#### Other Relevant Information